Professor Nicholas Turner is testing if combining a drug palbociclib together with the immunotherapy drug avelumab is safe and could be used to successfully treat a sub-type of triple negative breast cancer.

Dr Rachael Natrajan and her team are investigating whether triple negative breast cancer patients could benefit from the CDK4/6 inhibitor drug palbociclib. They want to find ways to predict which groups of patients could benefit from this drug and whose cancer might develop resistance to it.

Professor Pascal Meier is investigating new ways to improve treatment for triple negative breast cancer. He is looking for new combinations of treatment that work together to use the body’s ability to kill breast cancer cells.

Bosutinib is a drug that has been tested in breast cancer before but only worked for some patients. Professor Valerie Brunton’s team are trying to identify who are most likely to benefit from bosutinib, to bring new treatment options to those who need them.     

Professor Claire Lewis and her team are studying how the immune system can be used to destroy triple negative breast cancer. They are investigating whether a new combination of drugs, including avelumab, can boost the immune system’s response to a tumour.

Professor Bryan Hennessy, Dr Alex Eustace and colleagues are studying a drug gedatolisib, to understand which breast cancers are most susceptible to this treatment. Ultimately their research could improve the chances of survival for people with breast cancer.